GSBR-1290
Obesity
Key Facts
About Structure Therapeutics
Structure Therapeutics is on a mission to develop best-in-class oral small molecule therapeutics for validated but challenging G protein-coupled receptor (GPCR) targets, primarily in large markets like obesity and diabetes. Since its 2016 founding, the company has rapidly advanced a promising pipeline, most notably its GLP-1 receptor agonist GSBR-1290, and achieved a successful public listing, reflecting strong investor confidence in its differentiated structural biology platform. Its strategy hinges on using atomic-level insights to design superior oral drugs that could capture significant market share from incumbent injectable therapies.
View full company profileAbout Structure Therapeutics
Structure Therapeutics is on a mission to develop best-in-class oral small molecule therapeutics for validated but challenging G protein-coupled receptor (GPCR) targets, primarily in large markets like obesity and diabetes. Since its 2016 founding, the company has rapidly advanced a promising pipeline, most notably its GLP-1 receptor agonist GSBR-1290, and achieved a successful public listing, reflecting strong investor confidence in its differentiated structural biology platform. Its strategy hinges on using atomic-level insights to design superior oral drugs that could capture significant market share from incumbent injectable therapies.
View full company profileTherapeutic Areas
Other Obesity Drugs
| Drug | Company | Phase |
|---|---|---|
| LET003 | Harbour BioMed | Discovery |
| LET001 | Harbour BioMed | Discovery |
| RGT-075 | Regor Therapeutics | Phase 2b |
| Anti‑Obesity Oral Drug | Premas Biotech | Phase 1 |
| Obesity Target Discovery Collaboration | Fauna Bio | Target Discovery/Preclinical |
| GLP-1 variants | Heligenics | Discovery |
| MYO Platform (Metabolic Disease) | Renbio | Pre-clinical |
| Obesity Clinical Trials | IMA Clinical Research | Not Applicable (Service) |
| KAYO-2000 | KayoThera | Preclinical |
| MVD-1 (SANA) | Eolo Pharma | Phase 1 |
| GIP-neutralizing antibody | Helicore Biopharma | Pre-clinical |
| Antral Gastroplasty / Endoscopic Sleeve | Endo-TAGSS | Pre-clinical |